Other Information.
−Removed: Agreement and Plan of Merger, dated June 17, 2020, by and among the Olivia Ventures, Inc., Merger Sub, a Delaware corporation and wholly-owned subsidiary of Olivia Ventures, Inc., and Compass Therapeutics LLC, a Delaware limited liability company (incorporated by reference to the indicated exhibit in our Current Report on Form 8-K filed on June 23, 2020)
−Removed: Certificate of Merger relating to the merger of Merger Sub with and into Compass Therapeutics LLC, filed with the Secretary of State of the State of Delaware on 17, 2020 (incorporated by reference to the indicated exhibit in our Current Report on Form 8-K filed on June 23, 2020)
Amended and Restated Certificate of Incorporation, filed with the Secretary of State of the State of Delaware on June 17, 2020 (incorporated by reference to the indicated exhibit in our Current Report on Form 8-K filed on June 23, 2020)
Amended and Restated Bylaws (incorporated by reference to the indicated exhibit in our Current Report on Form 8-K filed on June 23, 2020)
−Removed: 2020 Stock Option and Incentive Plan (incorporated by reference to the indicated exhibit in our Current Report on Form 8-K filed on June 23, 2020)
−Removed: 2020 Senior Executive Cash Incentive Bonus Plan (incorporated by reference to the indicated exhibit in our Current Report on Form 8-K filed on June 23, 2020)
−Removed: Offer letter, dated November 8, 2017, between Vered Bisker-Leib and Compass Therapeutics LLC (incorporated by reference to the indicated exhibit in our Current Report on Form 8-K filed on June 23, 2020)
−Removed: Form of Indemnification Agreement (directors) (incorporated by reference to the indicated exhibit in our Current Report on Form 8-K filed on June 23, 2020)
−Removed: Form of Indemnification Agreement (executive officers) (incorporated by reference to the indicated exhibit in our Current Report on Form 8-K filed on June 23, 2020)
−Removed: Form of Pre-Merger Indemnification Agreement (directors and executive officers) (incorporated by reference to the indicated exhibit in our Current Report on Form 8-K filed on June 23, 2020)
−Removed: Registration Rights Agreement, dated June 19, 2020, by and among the Compass Therapeutics, Inc.
−Removed: and the parties thereto (incorporated by reference to the indicated exhibit in our Current Report on Form 8-K filed on June 23, 2020)
−Removed: Subscription Agreement, dated June 19, 2020, by and between Compass Therapeutics, Inc.
−Removed: and the investors party thereto (incorporated by reference to the indicated exhibit in our Current Report on Form 8-K filed on June 23, 2020)
−Removed: Amended and Restated Collaboration Agreement, dated February 11, 2015, by and between Adimab LLC and Kairos Biologics Foundation LLC (incorporated by reference to the indicated exhibit in our Current Report on Form 8-K filed on June 23, 2020)
−Removed: Loan and Security Agreement, dated March 30, 2018, by and between Pacific Western Bank, Inc., Compass Therapeutics, LLC and Compass Therapeutics Advisors, Inc.
−Removed: (incorporated by reference to the indicated exhibit in our Current Report on Form 8-K filed on June 23, 2020)
−Removed: First Amendment to Loan and Security Agreement, dated September 26, 2018, by and between Pacific Western Bank, Inc., Compass Therapeutics, LLC and Compass Therapeutics Advisors, Inc.
−Removed: (incorporated by reference to the indicated exhibit in our Current Report on Form 8-K filed on June 23, 2020)
−Removed: Second Amendment to Loan and Security Agreement, dated March 8, 2019, by and between Pacific Western Bank, Inc., Compass Therapeutics, LLC and Compass Therapeutics Advisors, Inc.
−Removed: (incorporated by reference to the indicated exhibit in our Current Report on Form 8-K filed on June 23, 2020)
−Removed: Third Amendment to Loan and Security Agreement, dated October 29, 2019, by and between Pacific Western Bank, Inc., Compass Therapeutics, LLC and Compass Therapeutics Advisors, Inc.
−Removed: (incorporated by reference to the indicated exhibit in our Current Report on Form 8-K filed on June 23, 2020)
−Removed: Sublease Agreement, dated July 29, 2016, by and between Horizon Discovery, Inc.
−Removed: and Compass Therapeutics, LLC (incorporated by reference to the indicated exhibit in our Current Report on Form 8-K filed on June 23, 2020)
−Removed: Sublease Modification Agreement, dated January 17, 2018, by and between Horizon Discovery, Inc.
−Removed: and Compass Therapeutics, LLC (incorporated by reference to the indicated exhibit in our Current Report on Form 8-K filed on June 23, 2020)
Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
10 unchanged sentences
XBRL Taxonomy Extension Presentation Linkbase Document
−Removed: Indicates a management contract or compensatory plan.
−Removed: Portions of this exhibit (indicated by asterisks) have been omitted in accordance with the rules of the SEC.
Filed herewith.
These exhibits are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall such exhibits be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act or the Exchange Act, except as otherwise stated in such filing.
−Removed: Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
−Removed: August 13, 2020
+Added: Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
+Added: November 09, 2020
/s/ Thomas Schuetz
1 unchanged sentence
Co-Founder and Chief Executive Officer
−Removed: August 13, 2020
+Added: November 09, 2020
/s/ Vered Bisker-Leib
Vered Bisker-Leib, PhD
−Removed: Chief Operating Officer
+Added: President and Chief Operating Officer
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.